Jason Napodano | TalkMarkets | Page 3

All Contributions

Latest Posts
33 to 48 of 54 Posts
<<< 1 2 3 4 >>>
VistaGen Licenses Regenerative Medicine Technology To BlueRock Therapeutics
Thursday, December 15, 2016 10:41 AM EDT
The agreement provides some nice potential upside in terms of future milestones and royalties from BlueRock. It also provides VistaGen a roadmap to monetize other aspects of its hPSC platform for cell therapy and regenerative medicine applications.
In this article: VTGN
Read
Cannabis Industry Should Benefit From The 21st Century Cures Act
Wednesday, December 14, 2016 1:38 PM EDT
The cannabis industry should benefit greatly from the passing of the Cures Act. The medical benefits of marijuana, or more specifically, cannabinoids, are real.
In this article: VBIO
Read
MS An Interesting Upshot Opportunity For RedHill's RHB-104
Tuesday, December 13, 2016 12:14 PM EDT
RedHill has numerous catalysts on the horizon that should make the next six to nine months a good time to be a shareholder, including the potential closing of a product acquisition or in-licensing in the next few weeks.
In this article: RDHL
Read
Matinas Expands Pipeline, Moves MAT2501 Into Phase 1
Monday, December 12, 2016 1:07 PM EDT
Matinas BioPharma is vastly undervalued at today's level of only $85 million. My valuation for the company's product MAT2203 is $400 million.
In this article: MTNB
Read
Vaxil Bio's ImMucin Is A Novel Neoantigen With Significant Anticancer Potential
Monday, December 12, 2016 11:33 AM EDT
ImMucin is expected to qualify as an Orphan Drug in the U.S., which will provide certain cost and time advantages to development, as well as market exclusivity one approved. I expect the company to move into Phase 2 in 2017.
In this article: VXLLF
Read
Did Congress Just Kick Off A New Bio Bubble?
Thursday, December 8, 2016 11:21 AM EDT
The U.S. Government, through its domestic and foreign policy, as well as both fiscal and monetary policy, is the single biggest creator of financial bubbles.
In this article: IBB
Read
ORY-1001 Phase 1 Data At ASH In AL Looks Good For Oryzon, Roche
Wednesday, December 7, 2016 11:19 AM EDT
Oryzon is focused on developing epigenetic-based therapies and personalized drugs from its proprietary platform technology. Oryzon currently trades on the Madrid Stock Exchange with a market capitalization of approximately €145 million.
Read
Vitality Biopharma Taking Cannabinoid Research To The Next Level
Wednesday, November 30, 2016 12:14 PM EDT
The medical marijuana and cannabis industry in the U.S. is booming. Vitality Bio is currently conducting preclinical studies in anticipation of filing IND applications in 2017 for glycosylated cannabinoid products called cannabosides.
In this article: VBIO
Read
Interview With Neurologist And ALS KOL Sheds Light On Brainstorm's Potential With NurOwn
Monday, November 28, 2016 1:05 PM EDT
BrainStorm stock is looking extremely interesting to me at this level. Investor concerns over an imminent massive dilutive offering are misguided. BrainStorm entered October 2016 with $11.2 million in cash.
In this article: BCLI
Read
Matinas Initiates Important Phase 2 Study With MAT2203
Monday, November 21, 2016 1:22 PM EDT
Matinas BioPharma Holdings, Inc. announced the commencement of dosing in a Phase 2 clinical study examining MAT2203 in patients with vulvovaginal candidiasis (VVC).
In this article: MTNB
Read
RedHill Expects An Eventful Next Few Months
Wednesday, November 16, 2016 2:41 PM EDT
RedHill's stock has taken a bit of a hit over the past few months. The shares peaked at over $16 in August 2016 and have pulled back to $11 today.
In this article: RDHL
Read
MabVax Reports Highly Encouraging Phase 1 Data In Pancreatic Cancer
Tuesday, November 15, 2016 3:34 PM EDT
MabVax Therapeutics, Inc. is an incredibly intriguing and undervalued biopharma company. Management is currently examining MVT-5873 and MVT-2163 in a Phase 1 clinical study for the treatment and detection of metastatic pancreatic cancer.
In this article: MBVX
Read
Valeritas Q3 Numbers Show Progress
Monday, November 14, 2016 10:06 AM EDT
Total revenues for the quarter were $4.9 million, an increase of 3% over the third quarter 2015. Revenues were slightly above my expectations of $4.8 million.
In this article: VLRX
Read
ASH Abstract Confirms Positive Outlook For Actinium's Actimab-A
Wednesday, November 9, 2016 3:46 PM EDT
Actinium now has a validated safe and effective treatment for elderly patients with newly-diagnosed AML progressing in a Phase 2 clinical study. Importantly, the Phase 1 data shows that at 2 µCi/kg, the CR rate was 50%
In this article: ATNM
Read
Matinas MAT2203 Could Be A Game-Changer
Monday, November 7, 2016 1:08 PM EDT
Despite all these aggressive measures, I still find Matinas Biopharma shares to be 140% under-valued today. Major catalysts are underway and I expect significant value inflection in the next 6-8 months.
In this article: MTNB
Read
CanFite's Piclidenoson Positioned For Successful Phase 3 In Psoriasis
Wednesday, November 2, 2016 3:01 PM EDT
Can-Fite BioPharma Ltd. announced that the company reached an agreement with the European Medicines Agency on the final design of a global pivotal Phase 3 trial for its lead drug candidate, piclidenoson, in the treatment of psoriasis.
In this article: CANF
Read
33 to 48 of 54 Posts
<<< 1 2 3 4 >>>